CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
November 28, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Doris Stacey Gama
Re: | CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration No. 333-267975 | |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 1:00 P.M. (Eastern Time) on November 29, 2022, or as soon thereafter as possible on such date.
Very truly yours,
CNS Pharmaceuticals, Inc. |
||
By: | /s/Christopher Downs | |
Name: Christopher Downs Title: Chief Financial Officer |